Eastman Kodak Co

Eastman Kodak Co(KODK)のニュースとイベント

$9.040

-0.410 (-4.54%)終値時点

KODK のニュース

KODK のイベント

7/1 16:30

Selling Stockholders Plan to Sell 4.43M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 4.43M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

5/7 16:41

Kodak Reports Q1 Revenue of $265M

Reports Q1 revenue $265M vs. $247M last year. "In the first quarter, Kodak achieved year-over-year improvement in key metrics, including revenue, gross profit and Operational EBITDA," said Jim Continenza, Kodak's Executive Chairman and CEO. "We have delivered three consecutive quarters of strong performance, despite a highly volatile and challenging business environment. Our success is no accident. It reflects several years of investing in innovation and infrastructure and focusing on operational excellence. Looking forward, we plan to build on our momentum by continuing to put our customers first, strengthen our balance sheet and invest in businesses that will drive future growth."

3/26 06:20

Kodiak's Zenkuda Shows Significant Results in Diabetic Retinopathy Treatment

Kodiak announced topline results in the GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy. In GLOW2, patients were randomized to receive either sham injection or Zenkuda via intravitreal injection at progressively extended intervals after a loading phase, with all patients on 6-month dosing by the end of the study. A total of 62.5% of patients treated with Zenkuda achieved a greater than or equal to 2-step improvement in DRSS score at Week 48, compared with 3.3% in the sham group, meeting the primary endpoint of superiority to sham with high statistical significance. Zenkuda also demonstrated superiority in the two alpha-controlled secondary endpoints, with high statistical significance: Zenkuda demonstrated superiority in the key secondary endpoint of reducing the risk of developing prespecified sight-threatening complications, including new or worsening proliferative DR or center-involving DME, by 85% compared to sham through Week 48. These results support the GLOW1 study results, in which Zenkuda reduced this risk by 89%. Overall,13.7% of patients on Zenkuda achieved a greater than or equal to3-step improvement in DRSS versus 0% with sham, an improvement comparable to GLOW1, in which 5.6% of patients on Zenkuda achieved a greater than or equal to3-step improvement in DRSS versus 0% with sham. Zenkuda was well-tolerated with low rates of common ocular adverse events. Notably, no cases of intraocular inflammation were reported in the study, and no cases of retinal vasculitis or occlusive retinal vasculitis were observed. The incidence of cataract in the study eye was low and in line with expected background rates in patients with DR. Consistent with a real-world diabetic patient population, GLOW2 included patients using GLP-1 medications. These patients were well-balanced between treatment arms. Among patients using GLP-1 medications, Zenkuda achieved a greater than or equal to 2-step improvement in DRSS from baseline to Week 48 in 60% of patients compared with 64.3% in patients not using GLP-1 medications.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める